Low-dose aspirin (ASA) renders human platelets more vulnerable to inhibition of aggregation by prostacyclin (PGI2)

This publication has 17 references indexed in Scilit:

• Minimal daily dosage of ASA for platelet inhibition.
  Stroke, 1982
• Low dose aspirin, platelet function and prostaglandin synthesis: Influence of epinephrine and alpha adrenergic blockade
  Prostaglandins and Medicine, 1981
• Possible significance of small numbers of functional platelets in a population of aspirin-treated platelets in vitro and in vivo
  Thrombosis Research, 1980
• DIFFERENTIAL INHIBITION OF PROSTACYCLIN PRODUCTION AND PLATELET AGGREGATION BY ASPIRIN
  The Lancet, 1979
• The Inhibitory Effect of Aspirin on Platelet and Vascular Prostaglandins in Rats cannot be Completely Dissociated
  British Journal of Haematology, 1979
• Independence of the cyclic amp-lowering activity of thromboxane a2 from the platelet release reaction
  Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1979
• Pharmacokinetics of Salicylate in Man
  Drug Metabolism Reviews, 1979
• HUMAN ARTERIAL AND VENOUS TISSUES GENERATE PROSTACYCLIN (PROSTAGLANDIN X), A POTENT INHIBITOR OF PLATELET AGGREGATION
  The Lancet, 1977
• Relative potencies of dipyridamole and related agents as inhibitors of cyclic nucleotide phosphodiesterases: Possible explanation of mechanism of inhibition of platelet function
  Life Sciences, 1975
• REDUCTION OF THROMBUS FORMATION ON DIALYSER MEMBRANES BY ASPIRIN AND RA 233
  The Lancet, 1972